Evidence map›Paper›PMID 25887352›Full record

ArticleGenome biology2015

CopywriteR: DNA copy number detection from off-target sequence data.

Thomas Kuilman, Arno Velds, Kristel Kemper, Marco Ranzani, Lorenzo Bombardelli, Marlous Hoogstraat, Ekaterina Nevedomskaya, Guotai Xu, Julian de Ruiter, Martijn P Lolkema and 7 more

Abstract read
In one paragraph

Article in Genome biology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 146 papers.

0numbers the graph read from it
0cells of the map it votes in
146citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

146 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

86 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Thomas KuilmanDivision of Molecular Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. t.kuilman@nki.nl.
Arno VeldsCentral Genomic Facility, Netherlands Cancer Institute, Amsterdam, The Netherlands. a.velds@nki.nl.
Kristel KemperDivision of Molecular Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. k.kemper@nki.nl.
Marco RanzaniExperimental Cancer Genetics, Wellcome Trust Sanger Institute, Hinxton, UK. mr10@sanger.ac.uk.
Lorenzo BombardelliDivision of Molecular Genetics, Netherlands Cancer Institute, Amsterdam, The Netherlands. l.bombardelli@nki.nl.
Marlous HoogstraatDivision of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, The Netherlands. m.hoogstraat@nki.nl.
Ekaterina NevedomskayaDivision of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, The Netherlands. e.nevedomskaya@nki.nl.
Guotai XuDivision of Molecular Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. g.xu@nki.nl.
Julian de RuiterDivision of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, The Netherlands. j.d.ruiter@nki.nl.
Martijn P LolkemaCenter for Personalized Cancer Treatment, Amsterdam, The Netherlands. M.Lolkema@erasmusmc.nl.
Bauke YlstraDepartment of Pathology, VU University Medical Center, Amsterdam, The Netherlands. b.ylstra@vumc.nl.
Jos JonkersDivision of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands. j.jonkers@nki.nl.
Sven RottenbergDivision of Molecular Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. s.rottenberg@nki.nl.
Lodewyk F WesselsDivision of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, The Netherlands. l.wessels@nki.nl.
David J AdamsExperimental Cancer Genetics, Wellcome Trust Sanger Institute, Hinxton, UK. da1@sanger.ac.uk.
Daniel S PeeperDivision of Molecular Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. d.peeper@nki.nl.
Oscar KrijgsmanDivision of Molecular Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. o.krijgsman@nki.nl.

Funding

Cancer Research UK 13031
6 · The paper itself

Abstract

Current methods for detection of copy number variants (CNV) and aberrations (CNA) from targeted sequencing data are based on the depth of coverage of captured exons. Accurate CNA determination is complicated by uneven genomic distribution and non-uniform capture efficiency of targeted exons. Here we present CopywriteR, which eludes these problems by exploiting 'off-target' sequence reads. CopywriteR allows for extracting uniformly distributed copy number information, can be used without reference, and can be applied to sequencing data obtained from various techniques including chromatin immunoprecipitation and target enrichment on small gene panels. CopywriteR outperforms existing methods and constitutes a widely applicable alternative to available tools.

Indexed as

Genome, HumanAlgorithmsDNA Copy Number VariationsExomeExonsHigh-Throughput Nucleotide SequencingHumansSequence Analysis, DNA

Identifiers

PMID25887352
PMCPMC4396974

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.